GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Pretax Margin %

InMed Pharmaceuticals (InMed Pharmaceuticals) Pretax Margin % : -146.89% (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. InMed Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2024 was $-1.72 Mil. InMed Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $1.17 Mil. Therefore, InMed Pharmaceuticals's pretax margin for the quarter that ended in Mar. 2024 was -146.89%.

The historical rank and industry rank for InMed Pharmaceuticals's Pretax Margin % or its related term are showing as below:

INM' s Pretax Margin % Range Over the Past 10 Years
Min: -1707.99   Med: -949.92   Max: -107.98
Current: -107.98


INM's Pretax Margin % is ranked better than
52.83% of 1024 companies
in the Biotechnology industry
Industry Median: -152.6 vs INM: -107.98

InMed Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for InMed Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Pretax Margin % Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -1,707.99 -191.85

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -193.04 -14.58 -281.26 -119.19 -146.89

Competitive Comparison of InMed Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, InMed Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Pretax Margin % falls into.



InMed Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

InMed Pharmaceuticals's Pretax Margin for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-7.935/4.136
=-191.85 %

InMed Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-1.723/1.173
=-146.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InMed Pharmaceuticals  (NAS:INM) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


InMed Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg officer: VP, Chem/Manufacturing/Control C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4